STAT reports that Novo Nordisk previously shelved a promising triple agonist targeting GLP-1, GIP, and glucagon due to safety concerns, allowing Eli Lilly to advance its own candidate, retatrutide. While Novo focused on semaglutide (Wegovy), the decision highlights a conservative corporate culture that may have cost them their lead in the obesity market as retatrutide progresses through late-stage trials.